by Plus Therapeutics | Mar 20, 2025 | GBM, LM, PBC, Uncategorized
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
by Plus Therapeutics | Mar 17, 2025 | LM
Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...
by Plus Therapeutics | Mar 6, 2025 | LM
FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Lung Cancer Patients with Leptomeningeal Metastases We are thrilled to announce that the U.S. FDA has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of...
by Plus Therapeutics | Feb 28, 2025 | GBM, LM, PBC, Uncategorized
Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...
by Plus Therapeutics | Feb 26, 2025 | LM
BREAKING NEWS: ReSPECT-LM Phase 1 Single Dose Completed – Phase 2 Dose Determined We are thrilled to announce a major milestone in the ReSPECT-LM clinical trial! The Phase 1 single-dose portion of the trial is now complete, and the recommended Phase 2 dose (RP2D) for...
by Plus Therapeutics | Feb 25, 2025 | LM
Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...
Recent Comments